Taikang Life Insurance and Lilly Ventures Asia have contributed to a $59.7m round for Hangzhou Just Biotherapeutics, a Chinese spinout of US-based Just Biotherapeutics.

Insurance conglomerate Taikang Life and pharmaceutical firm Eli Lilly participated in a RMB400m ($59.7m) series B round for China-based biotherapeutics developer Hangzhou Just Biotherapeutics (Just China) today.

The round was led by Singapore state-owned investment firm Temasek and included financial services firm Bank of Hangzhou, Arch Venture Partners and Hangzhou Economic & Technological Development Area. Eli Lilly invested through corporate venturing unit Lilly Asia Ventures.

Just China was founded by Just Biotherapeutics, a US-based biotherapeutics technology developer, in February 2016.